Hematopoietic growth factors are naturally sourced hormone-like glycoproteins that regulate the proliferation, differentiation, and maturation of blood cells by binding to come to light receptors of specific cells. Hematopoiesis may be the processof blood cell formation that occurs in the bone marrow. Each cell comes from the pluripotent stem cell, probably the most primitive cell. The pluripotent stem cell can differentiate and mature into whether lymphoid or myeloid cell line.
Mature functioning cells include lymphocytes, erythrocytes, platelets, neutrophils, eosinophils, basophils, and monocytes. Hematopoietic growth factors can target cells of the specific cell line, which makes them single-lineage growth factors, or can simultaneously regulate several cell lines, classifying them as multilineage growth factors.
For instance, granulocyte colony-stimulating factor is really a single-lineage growth factor that affects only granulocytes. However, GM-CSF is really a multilineage growth factor that affects granulocytes, monocytes, and macrophages. Hematopoietic growth factors happen to be produced through genetic engineering technology by cloning them in mammalian, bacterial, or yeast host cells.
Hematopoietic growth factors have played a significant role in preventing infection in cancer patients by shortening the amount of neutropenia in those receiving chemotherapy. Patients can better tolerate the conventional treatment regimen and could have the ability to tolerate higher doses of chemotherapeutic agents, which might improve therapeutic outcomes.
Four hematopoietic growth factors happen to be approved by the FDA, and several other growth factors are being studied in many studies. Included in this are M-CSF, stem cell factor, megakaryocyte development and growth factor, IL-3, and GM-CSF/IL-3 fusion protein.
G-CSF is made by macrophages, endothelial cells, fibroblasts, neutrophils, and bone marrow stomal cells. They boost the quantity of granulocytes, particularly neutrophils. Filgrastim is really a recombinant human G-CSF produced in Escherichia coli. It's commercially accessible as Neupogen. Filgrastim was first approved to lower the incidence of infections in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy.
Recently, it received regulatory approval to be used in patients with nonmyeloid cancers undergoing autologous bone marrow transplantation, patients with severe chronic neutropenia, patients undergoing peripheral blood progenitor cell collection, and patients with acute myeloid leukemia receiving induction or consolidation chemotherapy.
Filgrastim is run intravenously orsubcutaneously at dosages which range from 5 to 10 mg/kg/day starting Twenty four hours following the last dose of chemotherapy and recurring before absolute neutrophil count exceeds 10,000/mL. The most typical side-effect is generalized bone pain, particularly in the back, pelvis, and sternum. The pain sensation usually occurs inside a 24-hour period because the neutrophil count starts to recover.
Our website is not responsible for the information contained by this article. Webworldarticles.com is a free articles resource thus practically any visitor can submit an article. However if you notice any copyrighted material, please contact us and we will remove the article(s) in discussion right away.
This article was sent to us by:
Duane Owens at
07262011
1. Chemotherapy and Biologic Response Modifiers in cancer treatment
All articles in this directory are property of their respective authors. Additionally, read our Privacy Policy
© 2010 WebWorldarticles.com - All Rights Reserved. Partners: Gunblade Saga